Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

SPINEWAY :Joseph Brigneaud nominated to Spineway's Board of Directors

Posted on: 07 Nov 17

Press release                                                                                                 Ecully, 7 November 2017

Joseph Brigneaud nominated to
Spineway's Board of Directors

The Board of Directors of Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), has co-opted Mr. Joseph Brigneaud as an independent Board member.

Joseph Brigneaud, a partner at MAELO Capital - a private-equity investment firm, has over 15 years' experience in supporting and financing companies. Having opened and headed Euronext's regional office in Lyon for three years, he has considerable expertise in listed SMEs and mid-cap companies.

As from 23 October 2017, the composition of Spineway's Board of Directors is as follows:

  • Stéphane Le Roux , Chairman of the Board - Chairman and CEO of Spineway.
  • Philippe Laurito , Board member - Managing Director of Spineway, President of Spineway USA, Inc.
  • Bérangère Boggio, Independent Board member - Director of Legal Affairs and HR at MEDAC since 2013 after seven years with the MYLAN pharmaceutical group.
  • Joseph Brigneaud , Independent Board member.

Stéphane Le Roux, Chairman and CEO of Spineway, said, "We are thrilled to welcome Joseph Brigneaud as a member of our Board of Directors. His perfect understanding of the stock markets and his expertise in growing SMEs will help us increase our development and successfully pursue our geographic expansion."


SPINEWAY will be attending the SFAF Mid-Caps conference on 14 November 2017

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its turnover comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), received the OSEO Excellence award as well as the Deloitte Fast 50 award in 2011. Rhône Alpes INPI Patent Innovation Award (2013) - Talent INPI award (2015).
ISIN code: FR0011398874 - Euronext Growth

This press release is entered into in both English and French languages. In case of discrepancies, French language shall prevail.


Investor Relations
David Siegrist - Finance Director
+33 (0)4 72 77 01 52








Financial Communication
Jérôme Gacoin / Solène Kennis
+33 (0)1 75 77 54 68
Spineway's Board of Directors

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: SPINEWAY via GlobeNewswire

Last updated on: 08/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.